InMed Pharmaceuticals files prospectus supplement for at-the-market share offering

2026-04-04 02:27:02

Abstract generation in progress

InMed Pharmaceuticals Inc. has filed a prospectus supplement and related prospectus with the SEC to sell common shares under an existing at-the-market offering agreement with H.C. Wainwright & Co., LLC. This filing allows the company to sell shares directly into the market periodically. The offering is based on a shelf registration statement declared effective by the SEC on March 30, 2026.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.